PMID- 9845859
OWN - NLM
STAT- MEDLINE
DCOM- 19981222
LR  - 20190905
IS  - 0954-6820 (Print)
IS  - 0954-6820 (Linking)
VI  - 244
IP  - 5
DP  - 1998 Nov
TI  - Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I 
      is protective for the incidence of primary acute myocardial infarction in 
      middle-aged males. An incident case-control study from Sweden.
PG  - 425-30
AB  - OBJECTIVE: To further establish the importance of total plasma apolipoprotein A-I 
      and lipoprotein(a) in the prediction of primary acute myocardial infarction (AMI) 
      in men. DESIGN: An incident case-control study. SETTING: The study was nested 
      within the Vasterbotten Intervention Program (VIP) and the Northern Sweden MONICA 
      cohorts. SUBJECTS: A total of 62 male AMI cases and 124 matched controls, 
      randomly selected from the study cohorts. RESULTS: In multivariate logistic 
      regression, significant odds ratios (OR) were found for Lp(a) above 200 mg L-1, 
      apo A-I below the mean value (1136 mg L-1) and total cholesterol (TC) above 7.8 
      mmol L-1. TC interacted significantly with Lp(a); for Lp(a) above 200 mg L-1 and 
      TC below 6.5 mmol L-1, OR = 5.6; for Lp(a) above 200 mg L-1 and TC above 6.5 mmol 
      L-1, OR = 12.6. To evaluate the potential effect of reducing high levels of Lp(a) 
      or TC on the incidence of AMI in males, the attributable risk percentage (ARP) 
      was calculated when interaction between the two variables was present. ARP is 31% 
      for Lp(a) and 21% for TC, implying that 31% of the cases are due to high Lp(a) 
      and 21% of the cases are due to high TC levels. CONCLUSIONS: In the Swedish male 
      population, total apo A-I in plasma is a protective factor and a plasma Lp(a) 
      level above 200 mg L-1 is a risk factor for AMI in males. A TC level above 6.5 
      mmol L-1 increased the risk of AMI if the Lp(a) level was above 200 mg L-1, 
      suggesting Lp(a) to be useful in identifying high risk individuals needed to be 
      treated.
FAU - Dahlen, G H
AU  - Dahlen GH
AD  - Department of Clinical Chemistry, Umea University, Sweden. 
      gosta.h.dahlen@klinkemi.umu.se
FAU - Weinehall, L
AU  - Weinehall L
FAU - Stenlund, H
AU  - Stenlund H
FAU - Jansson, J H
AU  - Jansson JH
FAU - Hallmans, G
AU  - Hallmans G
FAU - Huhtasaari, F
AU  - Huhtasaari F
FAU - Wall, S
AU  - Wall S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Lipoprotein(a))
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
CIN - J Intern Med. 2001 Sep;250(3):265-7. PMID: 11555135
MH  - Apolipoprotein A-I/*blood
MH  - Case-Control Studies
MH  - Cholesterol/*blood
MH  - Humans
MH  - Incidence
MH  - Lipoprotein(a)/*blood
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*blood/etiology
MH  - Odds Ratio
MH  - Risk Factors
MH  - Sweden
EDAT- 1998/12/10 00:00
MHDA- 1998/12/10 00:01
CRDT- 1998/12/10 00:00
PHST- 1998/12/10 00:00 [pubmed]
PHST- 1998/12/10 00:01 [medline]
PHST- 1998/12/10 00:00 [entrez]
AID - 10.1046/j.1365-2796.1998.00422.x [doi]
PST - ppublish
SO  - J Intern Med. 1998 Nov;244(5):425-30. doi: 10.1046/j.1365-2796.1998.00422.x.